Biovie Inc. (BIVIW) — SEC Filings
Biovie Inc. (BIVIW) — 44 SEC filings. Latest: 8-K (Nov 13, 2025). Includes 21 8-K, 6 10-Q, 4 DEF 14A.
Overview
Biovie Inc. (BIVIW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 13, 2025: BioVie Inc. filed an 8-K on November 13, 2025, reporting on events as of November 10, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 4 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Biovie Inc. is neutral.
Filing Type Overview
Biovie Inc. (BIVIW) has filed 21 8-K, 6 10-Q, 4 DEF 14A, 2 10-K, 4 S-1/A, 2 S-1, 1 SC 13G, 3 8-K/A, 1 SC 13D/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of BIVIW's 39 recent filings, 4 were flagged as high-risk, 26 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $ -5,087,557 |
| EPS | $ -0.98 |
| Debt-to-Equity | 0.08 |
| Cash Position | $ 24,978,302 |
| Operating Margin | -99.8% |
| Total Assets | $ 26,820,098 |
| Total Debt | $ 1,899,094 |
Key Executives
- James Lang
- Cuong Do
- Board of Directors
- Dr. Babak B. Moussavi
- Ms. Sarah E. Empey
- Terren S. Peizer
Industry Context
The biotechnology sector is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like BioVie Inc. operate in a competitive landscape where innovation is key, but success is often dependent on clinical trial outcomes and securing substantial funding. The focus on neurodegenerative diseases and unmet medical needs presents both opportunity and risk.
Top Tags
corporate-governance (9) · filing (6) · SEC Filing (5) · 10-Q (5) · amendment (5) · shareholder-vote (4) · Biotechnology (4) · material-agreement (4) · equity-sale (4) · Capital Raise (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $5,087,557 | for the three months ended September 30, 2025, increased from $4,152,032 in 2024 |
| Research and Development Expenses | $2,936,370 | for the three months ended September 30, 2025, up from $1,990,198 in 2024 |
| Cash and Cash Equivalents | $24,978,302 | as of September 30, 2025, up from $17,544,547 at June 30, 2025 |
| Net Proceeds from Common Stock Issuance | $10,457,629 | for the three months ended September 30, 2025 |
| Clinical Trial Grant | $13.1 million | awarded from U.S. Department of Defense for Long COVID program in April 2024 |
| Shares of Class A Common Stock Outstanding | 7,540,316 | as of November 7, 2025 |
| Study Sites | 15 | with significant protocol deviations in the Phase 3 Alzheimer's trial |
| Patients | 81 | remaining in the Modified Intent to Treat population after exclusions in the AD trial |
| Accumulated Deficit | $357,275,347 | as of September 30, 2025 |
| Grant Reimbursements | $336,000 | recognized for R&D expenses in Q3 2025 for Long COVID program |
| Shares authorized for 2019 Omnibus Equity Incentive Plan | 3,100,000 | Proposed increase, potentially leading to significant dilution for existing shareholders. |
| Shares of common stock outstanding | 7,535,080 | Total shares entitled to vote as of the September 22, 2025 record date. |
| Annual Meeting Date | November 10, 2025 | Date when key proposals will be voted upon by stockholders. |
| Number of directors to be elected | 6 | Board Election Proposal seeks to elect six directors. |
| Quorum requirement | 33-1/3% | Percentage of shares required to be present for the Annual Meeting to be held. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Biovie Inc. (BIVIW)?
Biovie Inc. has 44 recent SEC filings from Jan 2024 to Nov 2025, including 21 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BIVIW filings?
Across 44 filings, the sentiment breakdown is: 4 bearish, 38 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Biovie Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biovie Inc. (BIVIW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biovie Inc.?
Key financial highlights from Biovie Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BIVIW?
The investment thesis for BIVIW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biovie Inc.?
Key executives identified across Biovie Inc.'s filings include James Lang, Cuong Do, Board of Directors, Dr. Babak B. Moussavi, Ms. Sarah E. Empey and 1 others.
What are the main risk factors for Biovie Inc. stock?
Of BIVIW's 39 assessed filings, 4 were flagged high-risk, 26 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Biovie Inc.?
Forward guidance and predictions for Biovie Inc. are extracted from SEC filings as they are enriched.